Trials / Completed
CompletedNCT04303819
The Effect of Exenatide on Fasting Bile Acids
The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Beijing Chao Yang Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.
Detailed description
Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exenatide treatment | 12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer. |
Timeline
- Start date
- 2020-01-05
- Primary completion
- 2020-01-28
- Completion
- 2020-01-31
- First posted
- 2020-03-11
- Last updated
- 2020-06-11
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04303819. Inclusion in this directory is not an endorsement.